Kairos Pharma publishes study showing CD105 blockade restores osimertinib sensitivity in NSCLC

Kairos Pharma, LTD.

Study in Drug Resistance Updates shows CD105 upregulation drives resistance to EGFR-targeted therapy osimertinib.
Preclinical models: ENV105 (carotuximab) combined with osimertinib restored drug sensitivity via metabolic reprogramming.
CEO states CD105 is a central resistance mechanism across prostate, breast, colon, and lung cancers.
ENV105 currently in Phase 2 for castrate-resistant prostate cancer and Phase 1 for lung cancer.
Global NSCLC treatment market projected to reach $45B by 2030; drug resistance remains a major challenge.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.